Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K7ZH
|
|||
| Former ID |
DIB013213
|
|||
| Drug Name |
PF-06649751
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-9: 332] | Phase 1 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H16F3N3O3
|
|||
| Canonical SMILES |
CC1=C(C=CC(=C1)OC2=C(C=CC=N2)C(F)(F)F)C3=C(C(=O)NC(=O)N3C)C
|
|||
| InChI |
1S/C19H16F3N3O3/c1-10-9-12(28-17-14(19(20,21)22)5-4-8-23-17)6-7-13(10)15-11(2)16(26)24-18(27)25(15)3/h4-9H,1-3H3,(H,24,26,27)
|
|||
| InChIKey |
AKQXQLUNFKDZBN-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1643489-24-0
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01981694) A Phase I Trial to Investigate the Safety and Tolerability of PF-06649751. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.